Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1951 1
1952 1
1954 2
1955 3
1956 5
1957 3
1965 1
1966 3
1967 2
1968 1
1970 2
1971 2
1972 3
1975 1
1980 3
1987 2
1994 1
2001 1
2002 2
2003 1
2004 1
2005 6
2006 9
2007 14
2008 9
2009 10
2010 8
2011 11
2012 17
2013 13
2014 12
2015 13
2016 17
2017 19
2018 21
2019 17
2020 18
2021 20
2022 17
2023 15
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

277 results

Results by year

Filters applied: . Clear all
Page 1
An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth.
Morgenstern A, Apostolidis C, Kratochwil C, Sathekge M, Krolicki L, Bruchertseifer F. Morgenstern A, et al. Curr Radiopharm. 2018;11(3):200-208. doi: 10.2174/1874471011666180502104524. Curr Radiopharm. 2018. PMID: 29732998 Free PMC article. Review.
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
Feuerecker B, Tauber R, Knorr K, Heck M, Beheshti A, Seidl C, Bruchertseifer F, Pickhard A, Gafita A, Kratochwil C, Retz M, Gschwend JE, Weber WA, D'Alessandria C, Morgenstern A, Eiber M. Feuerecker B, et al. Among authors: morgenstern a. Eur Urol. 2021 Mar;79(3):343-350. doi: 10.1016/j.eururo.2020.11.013. Epub 2020 Dec 5. Eur Urol. 2021. PMID: 33293081
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study.
Sathekge MM, Lawal IO, Bal C, Bruchertseifer F, Ballal S, Cardaci G, Davis C, Eiber M, Hekimsoy T, Knoesen O, Kratochwil C, Lenzo NP, Mahapane J, Maserumule LC, Mdlophane AH, Mokoala KMG, Ndlovu H, Pant V, Rathke H, Reed J, Sen IB, Singh A, Sood A, Tauber R, Thakral P, Yadav MP, Morgenstern A. Sathekge MM, et al. Among authors: morgenstern a. Lancet Oncol. 2024 Feb;25(2):175-183. doi: 10.1016/S1470-2045(23)00638-1. Epub 2024 Jan 11. Lancet Oncol. 2024. PMID: 38218192
Targeted alpha therapy for glioblastoma.
Kunikowska J, Morgenstern A, Pełka K, Bruchertseifer F, Królicki L. Kunikowska J, et al. Among authors: morgenstern a. Front Med (Lausanne). 2022 Dec 16;9:1085245. doi: 10.3389/fmed.2022.1085245. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36590948 Free PMC article. Review.
Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution?
Feuerecker B, Kratochwil C, Ahmadzadehfar H, Morgenstern A, Eiber M, Herrmann K, Pomykala KL. Feuerecker B, et al. Among authors: morgenstern a. J Nucl Med. 2023 May;64(5):685-692. doi: 10.2967/jnumed.122.265353. Epub 2023 Apr 13. J Nucl Med. 2023. PMID: 37055224 Review.
Advances in targeted alpha therapy of cancer.
Sathekge M, Morgenstern A. Sathekge M, et al. Among authors: morgenstern a. Eur J Nucl Med Mol Imaging. 2024 Apr;51(5):1205-1206. doi: 10.1007/s00259-024-06658-1. Eur J Nucl Med Mol Imaging. 2024. PMID: 38376807 No abstract available.
Variable staphyloxanthin production by Staphylococcus aureus drives strain-dependent effects on diabetic wound-healing outcomes.
Campbell AE, McCready-Vangi AR, Uberoi A, Murga-Garrido SM, Lovins VM, White EK, Pan JT, Knight SAB, Morgenstern AR, Bianco C, Planet PJ, Gardner SE, Grice EA. Campbell AE, et al. Among authors: morgenstern ar. Cell Rep. 2023 Oct 31;42(10):113281. doi: 10.1016/j.celrep.2023.113281. Epub 2023 Oct 19. Cell Rep. 2023. PMID: 37858460 Free PMC article.
Supply and Clinical Application of Actinium-225 and Bismuth-213.
Morgenstern A, Apostolidis C, Bruchertseifer F. Morgenstern A, et al. Semin Nucl Med. 2020 Mar;50(2):119-123. doi: 10.1053/j.semnuclmed.2020.02.003. Epub 2020 Feb 21. Semin Nucl Med. 2020. PMID: 32172796 Free PMC article. Review.
Targeted α-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment.
Ertveldt T, Krasniqi A, Ceuppens H, Puttemans J, Dekempeneer Y, Jonghe K, Mey W, Lecocq Q, Vlaeminck Y, Awad RM, Goyvaerts C, Veirman K, Morgenstern A, Bruchertseifer F, Keyaerts M, Devoogdt N, D'Huyvetter M, Breckpot K. Ertveldt T, et al. Among authors: morgenstern a. J Nucl Med. 2023 May;64(5):751-758. doi: 10.2967/jnumed.122.264752. Epub 2023 Apr 13. J Nucl Med. 2023. PMID: 37055223
277 results